By:
On:
In: Around the web
Tagged:
With: 0 Comments

Investors certainly have to be happy with Zebra Technologies Corp. [stckqut]ZBRA[/stckqut] and its short term performance. After all, the stock has jumped by 13.5% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ZBRA?

While we can never know for sure, it is pretty encouraging that estimates for ZBRA have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks.

Source: Can The Uptrend Continue for Zebra Technologies (ZBRA)? – May 19, 2015 – Zacks.com

By:
On:
In: Around the web
Tagged:
With: 0 Comments

The German company is pinning its health care hopes on successfully developing its anti-PDL1 immuno-oncology treatment in alliance with Pfizer. That puts the pharmaceutical and materials company in one of the hottest, but also most competitive, areas in health care. And Merck doesn’t have an obvious edge.

Merck’s [stckqut]MRK[/stckqut] first-quarter results Tuesday showed its challenges. Its biggest product, multiple sclerosis drug Rebif is in decline: sales excluding currency movements fell 15.9% in the first quarter from a year earlier, though still accounted for a quarter of Merck’s health care revenues.

Merck has been bulking up in more stable, higher-growth areas with last year’s acquisition of AZ Electronic Materials and its yet-to-close €13.1 billion deal to buy Sigma-Aldrich, the maker of life sciences tools.

At the same time, it is ramping up research and development spending to try to take on more advanced rivals like Bristol-Myers Squibb, Merck & Co. of the U.S., Roche and AstraZeneca in immuno-oncology. Up to 20 development programs could start this year, six of which could form the basis of a registration with U.S. regulators.

Source: Merck Could Struggle to Hit Health Care Heights

By:
On:
In: Around the web
Tagged:
With: 0 Comments

Of these three companies, I currently only track Skyworks Solutions on my WatchList.

Skyworks Solutions Inc (NASDAQ:SWKS) [stckqut]SWKS[/stckqut]

Headquartered in Woburn, MA, Skyworks Solutions, Inc. is the industry’s leading wireless semiconductor company focused on radio frequency (RF) and complete semiconductor system solutions for mobile communications applications.

This Zacks Rank #2 stock flaunts a Growth Style Score of ‘B’. Its EPS is expected to grow at a rate of 20.03% over the long term, ahead of the industry growth rate of 18.70%.

Skyworks has seen solid activity on the earnings estimate revision front as well. Over the past 30 days, estimates for the current year have moved up 3.1% to $4.69 a share, while for the next year it has improved 5.8% to $5.49 a share.

To top it all, the company belongs to the SEMI-RADIO FREQ industry, which presently lies in the top 1% of our 260 plus industries, indicating that the industry has improving earnings prospects and is in favor with the investors.

Source: 3 Tech Stocks to Celebrate the Bull Market Run: Skyworks Solutions Inc (SWKS), ARM Holdings plc (ARMH), Cascade Microtech, Inc. (CSCD) – Smarter Analyst

By:
On:
In: Around the web
Tagged:
With: 0 Comments

We look at Fossil Group, Inc. [stckqut]FOSL[/stckqut] a company in the Consumer Goods industry which traders have been highly interested in of late, to assess if it provides value for investors considering buying or selling it.

—

The stock has an estimated 5 year annual growth of 10.31% and a PEG multiple of 1.15.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if Fossil Group, Inc. is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of FOSL. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of FOSL being 1.15, we consider Fossil Group, Inc. to likely be priced at fair value.

Source: Is there Value for Investors: Fossil Group (NASDAQ:FOSL) – Stock Markets Daily

By:
On:
In: Around the web
Tagged:
With: 0 Comments

Cirrus Logic Inc. [stckqut]CRUS[/stckqut] is a semiconductor company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CRUS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Cirrus Logic could be a solid choice for investors.

In the past 60 days, [one] estimate [has] gone higher for Cirrus Logic while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 7 cents a share 30 days ago, to 23 today, a significant move.

Source: Why Cirrus Logic (CRUS) Could Be Positioned for a Surge? – May 4, 2015 – Zacks.com